Clinical Guidelines and Standards Guidelines by Clinical Area

Obstetric Care Consensus No. 7: Placenta Accreta Spectrum

American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine

Published December 2018 Obstetrics & Gynecology
DOI 10.1097/AOG.0000000000002983 PMID 30461695

RRM Academy Synopsis

Placenta accreta spectrum risk rises with each prior cesarean

The chance of placenta accreta spectrum rises with each prior cesarean delivery. Two obstetric groups said so in a 2018 consensus statement. It includes risks, imaging, delivery plans and ways to save the uterus.

Key Findings

  • In a systematic review, placenta accreta spectrum occurred in 0.3% of women with one previous cesarean delivery and in 6.74% of women with five or more.
  • For women with placenta previa, accreta risk climbed from 3% at the first cesarean to 11%, 40%, 61%, and 67% by the fifth or more.
  • Across 23 studies and 3,707 pregnancies, a systematic review found ultrasound had 90.72% sensitivity (95% CI, 87.2–93.6) and 96.94% specificity (95% CI, 96.3–97.5%).
  • The largest expectant management series found hysterectomy was needed in 22% (36/167) of women after expectant management was tried. Severe morbidity occurred in 6% (10/167).
  • The committee suggests scheduled delivery at 34 0/7–35 6/7 weeks for a stable patient. About one half of women beyond 36 weeks need emergency delivery for hemorrhage.

Interpretation

Two obstetric groups wrote this 2018 consensus statement. It pulls together published evidence and expert opinion on placenta accreta spectrum, and examines risk factors, imaging, delivery planning, and ways to save the uterus. The authors note that few randomized trials exist on this condition. The findings support more research into imaging and uterus-sparing care for placenta accreta spectrum.

RRM Context

Restorative reproductive medicine pays close attention to uterine history. The statement names past uterine surgery and Asherman syndrome as risk factors. Its top theory points to a flaw where the womb lining meets the muscle. Protecting the uterus is a restorative goal.

Abstract

Placenta accreta spectrum, formerly known as morbidly adherent placenta, refers to the range of pathologic adherence of the placenta, including placenta increta, placenta percreta, and placenta accreta. The most favored hypothesis regarding the etiology of placenta accreta spectrum is that a defect of the endometrial-myometrial interface leads to a failure of normal decidualization in the area of a uterine scar, which allows abnormally deep placental anchoring villi and trophoblast infiltration. Maternal morbidity and mortality can occur because of severe and sometimes life-threatening hemorrhage, which often requires blood transfusion. Although ultrasound evaluation is important, the absence of ultrasound findings does not preclude a diagnosis of placenta accreta spectrum; thus, clinical risk factors remain equally important as predictors of placenta accreta spectrum by ultrasound findings. There are several risk factors for placenta accreta spectrum. The most common is a previous cesarean delivery, with the incidence of placenta accreta spectrum increasing with the number of prior cesarean deliveries. Antenatal diagnosis of placenta accreta spectrum is highly desirable because outcomes are optimized when delivery occurs at a level III or IV maternal care facility before the onset of labor or bleeding and with avoidance of placental disruption. The most generally accepted approach to placenta accreta spectrum is cesarean hysterectomy with the placenta left in situ after delivery of the fetus (attempts at placental removal are associated with significant risk of hemorrhage). Optimal management involves a standardized approach with a comprehensive multidisciplinary care team accustomed to management of placenta accreta spectrum. In addition, established infrastructure and strong nursing leadership accustomed to managing high-level postpartum hemorrhage should be in place, and access to a blood bank capable of employing massive transfusion protocols should help guide decisions about delivery location.

Topics

By this author

Related research

Clinical Guidelines and Standards › Guidelines by Clinical Area › Obstetric Guidelines · Birth and Delivery › Birth Outcomes › Maternal Morbidity · Diagnostics › Ultrasound › Transvaginal Ultrasound
PMID 30461695 30461695 DOI 10.1097/AOG.0000000000002983 10.1097/AOG.0000000000002983 American College of Obstetricians and Gynecologists et al. 2018, American College of Obstetricians and Gynecologists 2018